Nobel Prize–winning scientist Jennifer Doudna is spearheading a $1 billion initiative designed to overcome the financial, regulatory, and infrastructure barriers that have slowed the commercialization of gene editing breakthroughs. The effort aims to accelerate the development and delivery of CRISPR-based therapies for rare and complex diseases, addressing the gap between groundbreaking lab discoveries and real-world patient access.
713-782-3777
